annb0t
Top 20
HEMGENIX® underscores CSL's promise to deliver life-changing innovations that have the potential to help patients lead full lives
MARBURG, Germany, Feb. 20, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) today announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B (congenital Factor IX defi...
>>> Read more: First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission
MARBURG, Germany, Feb. 20, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) today announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B (congenital Factor IX defi...
>>> Read more: First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission
